NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.
该合作包括一项将于2025年第二季度开始的1期临床研究。
The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.
新加坡国家皮肤中心、赛诺菲和科学、技术和研究局（A*STAR）签署了一份谅解备忘录（MoU），以推进痤疮治疗的研究。
The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.
该合作包括一项涉及轻度痤疮患者的1期临床研究，预计将于2025年第二季度开始。
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.
此外，将进行一项转化研究，以探索影响痤疮严重程度的关键生物标志物。
The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.
慢性炎症性皮肤病影响了很大一部分人群，大约80％的青少年和越来越多的成年人（估计占40％）患有这种疾病。
